随着NewAmsterdam Pharma Co NV (NASDAQ: ...

治疗原发性高胆固醇血症和混合型高脂血症以及杂合子型家族性高胆固醇血症（HeFH）均以NDA，预期分别在今年四季度和明年上半年获批。古莫奇单抗 ...

Conclusion: This is the first and largest randomised, controlled, long-term clinical study to test the efficacy, safety and tolerability of a statin in boys and girls with heFH. The baseline data ...

The heart-1 study is enrolling patients with an inherited form of very high cholesterol – heterozygous familial hypercholesterolaemia (HeFH) – that predisposes them to early development of ...

The future of CRISPR involves clinical trials focused on treatment for blood diseases and cancers, cardiovascular disease, ...

Patients have either been diagnosed with HeFH or premature coronary artery disease ("CAD"). The study is enrolling patients, and initial data is expected in the first half of next year - an ...

This includes patients with hypercholesterolemia (heterozygous familial and non-familial [HeFH]), patients whose condition is not responding adequately to statins or other lipid-lowering drugs ...

You have until October 28, 2024, to ask the Court to appoint you as Lead Plaintiff for the class if you are a shareholder who purchased or otherwise acquired Verve securities during the Class Period.

bringing NewAmsterdam closer to providing a new treatment option for heterozygous familial hypercholesterolemia (HeFH) and/or atherosclerotic cardiovascular disease (ASCVD). If successful ...

The employees received an aggregate of 12,600 restricted stock units (RSUs). The RSUs will vest in equal annual installments on the first four anniversaries of October 1, 2024, subject to each such ...

showing a significant LDL-C reduction in HeFH patients. The stock fell 8.35% despite the success, with analysts confident in future trial outcomes.